| Megan Lisska, MD | |
|
222 W 39th Ave, San Mateo, CA 94403-4364 | |
| (650) 573-2222 | |
| Not Available |
| Full Name | Megan Lisska |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 222 W 39th Ave, San Mateo, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164582359 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | A76321 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Megan Lisska, MD 222 W 39th Ave, San Mateo, CA 94403-4364 Ph: (650) 573-2222 | Megan Lisska, MD 222 W 39th Ave, San Mateo, CA 94403-4364 Ph: (650) 573-2222 |
News Archive
In a study titled "MicroRNA Modulation in Obesity and Periodontitis," lead author Romina Perri, University of North Carolina School of Dentistry, Oral Health Institute, conducted a pilot investigation to determine whether obesity or periodontal disease modified microRNA expression and whether there was any potential interaction between obesity and periodontitis that could involve microRNA modulation.
As the airport lounge filled with passengers waiting to board Malaysia Airlines Flight 17, a renowned professor rushed to the gate while texting a colleague, saying that he was "superbusy." Veering into the business-class line, Joep Lange, an AIDS researcher, passed a former election observer who had just returned from Ukraine.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).
› Verified 3 days ago
Jennie Yoo, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1950 Alameda De Las Pulgas, San Mateo, CA 94403 Phone: 650-570-3515 | |
Mariel Herbert, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 181 2nd Ave Ste 450, San Mateo, CA 94401 Phone: 415-922-9122 | |
Huaiyu Yang, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 222 W 39th Ave, San Mateo, CA 94403 Phone: 650-573-2426 | |
Denise Albert, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 999 Baker Way Ste 420, San Mateo, CA 94404 Phone: 650-571-9652 Fax: 650-571-9657 | |
Darshana Sachin Pai, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 177 Bovet Rd Ste 300, San Mateo, CA 94402 Phone: 650-627-1700 | |
Ms. Ryuko Ishikawa, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 138 E Hillsdale Blvd, San Mateo, CA 94403 Phone: 415-640-1455 | |
Elizabeth J Rody, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1950 Alameda De Las Pulgas, San Mateo, CA 94403 Phone: 650-587-8574 |